AMS HP eNews Bulletin 31 May 2016

--

  Australasian Menopause Society  
 
 
Health Professionals eNews31 May 2016
 
  ---  
  Welcome to AMS HP eNews for doctors and other healthcare professionals who have a special interest in women's health. The content covers information and resources relevant to menopause, midlife and the promotion of healthy ageing.

Contents
 
   

Are women suffering in silence? - UK survey public 

New survey puts spotlight on significant impact of menopause despite recent guideline.

 

Findings presented at the British Menopause Society’s annual conference today show only half of women surveyed in Great Britain (who are currently experiencing or who have experienced menopausal symptoms within the past ten years) consult a healthcare professional for any of their menopause symptoms. 

 

More than 200 leading women’s health experts from around the world gathered at the BMS’s annual conference to discuss recent advances in menopause research, and the impact of the National Institute of Health and Care Excellence (NICE) guideline on addressing the often overlooked needs of women experiencing the menopause. 

Some of the results were surprising...

readmore

 
   

Not all progestins are the same   

Assoc Prof John Eden

 

Assoc Professor John Eden spends ten minutes reviewing progestins in this Healthed video.  

 

readmore

 
   

Contraception - updated Information Sheet

contraception

Key points

  • While fertility declines with age, women are at risk of an unintended pregnancy until 12 months after the last menstrual period if over 50 years (24 months if below 50 years)
  • Women should be provided with evidence-based information about all contraceptive options in order to support informed decision making
  • Oestrogen containing methods (combined oral contraception and the vaginal ring) and the contraceptive injection are generally not recommended after 50 years as the cardiovascular risks outweigh the benefits
  • The LNG-IUD provides effective management of heavy menstrual bleeding as well as contraception and it can be used as part of an HRT regimen
  • Women in a new relationship should be advised about the use of condoms to prevent STIs
  • Women should be informed about the availability of the Emergency Contraceptive Pill without a prescription at pharmacies and its effectiveness up to 96 hours after unprotected intercourse 

readmoreSee www.menopause.org.au/for-women/information-sheets/1004-contraception 

 
   

Menopause Essentials Update for Health Professionals:
28 July 2016

Menopause Essentials Update for Health Professionals  28 July 2016 - Hotel Grand Chancellor, Hobart

This workshop is aimed at all GPs, specialists and allied health workers who are seeking a comprehensive update in the field of menopause. Prof Bronwyn Stuckey and Dr Jane Elliott will be presenting and providing case studies on the following topics:

 

Menopause: What is it? Prof Bronwyn Stuckey

How to manage menopause Dr Jane Elliott

Risks and benefits of HRT Prof Bronwyn Stuckey

Troubleshooting HRT, low libido and testosterone Dr Jane Elliottt  

 

Speakers


Professor Bronwyn Stuckey BA MBBS FRACP is President of the Australasian Menopause Society. Bronwyn is an endocrinologist with a clinical and research interest in reproductive endocrinology. She is Consultant Endocrinologist in the Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia and Clinical Professor in the School of Medicine and Pharmacology, University of Western Australia. She is also the Medical Director of the Keogh Institute for Medical Research which conducts both clinics and research for both men and women. The focus of her research and that of the Institute is on the interface between reproduction and reproductive hormones and metabolism.

 

Dr Jane Elliottt, MBBS, is a Past President and a Life Member of the Australasian Menopause Society. Jane is a general practitioner with a longstanding commitment in women’s health especially menopause and midlife women’s health. She is a Clinical Lecturer in the Discipline of Obstetrics and Gynaecology at the University of Adelaide and a member of the Medical and Scientific Committee of Osteoporosis Australia.

 

Venue: Hotel Grand Chancellor, Hobart

 

Registration: $50 for AMS Members, $75 for Non­‐members

 

Registration is now open here...

readmore

 
   

20th AMS Congress - Call for Abstracts 

AMS Annual Congress  Fremantle - Western Australia 18-20 November 2016This year our Congress will be at the Esplanade Hotel in Fremantle, right in the heart of the art and cafe culture of the historic port city and close by to beaches, the Swan river and Rottnest Island. 

 

Registrations open 1st June 2016. Until then you can be kept up to date with all the congress information by registering your interest here.

 

AMS invites the submission of papers on original work for consideration for the Congress Program. Authors are invited to submit abstracts for 15 minute oral and/or poster presentations for consideration by the AMS Scientific Program Committee. 

 

Abstracts may be submitted on any topic relevant to the menopause and its treatment. A link to Guidelines in Preparing and formatting your abstract are available from the AMS Website.

 

Abstract submissions close 13 August 2016

readmore

 
 

Join AMS for Member's only content

See exclusive commentary on studies such as:  

 

HRT: a change of view?

A recently published original article has described the results of an online survey taken in 2007 and compared the results with those of repeat survey in 2014. The aim was to illustrate women's views on HRT, and how they have changed over time, with respect to the availability of reliable information on the safety of, and access to, treatments for the symptoms of the menopause. Whilst the decreased use of HRT, following the unbalanced reporting of the Million Women Study, has been hailed by some as economically beneficial, there are others who describe these years as a lost decade, with missed opportunities to prevent and manage chronic diseases...

 

Hormone therapy in women with elevated risk for cardiovascular disease 

Two recent guidelines on menopause management have been published and have already been discussed separately in our web-based educational program. Yet, I felt that head-to-head comparison of both guidelines in regard to postmenopausal hormone therapy (HT) is worthwhile since it shows the small, but somewhat significant differences in approach concerning cardiovascular safety...

 

The FDA Office of Women's Health report 

The US Food and Drug Administration Office of Women’s Health (FDA OWH) has just published an update on its activities during the recent years [1]. This report opens a window on current FDA fields of interest in women's health. Evidently, the role of any regulatory agency is, first, to optimize medical product development and to evaluate product safety and efficacy. OWH also invests in research projects and dictates the exact trial design, and the type of data to be collected and analyzed. Among the fields on which the OWH has focused were early detection of breast cancer, lung cancer in women, vertebroplasty for osteoporotic fracture, HIV, and pregnancy...

 

Climacteric E-alert - Volume 19, Number 3

EDITORIAL: Menopause in the 21st century: the need for research and development
Nick Panay and Anna Fenton
As the global population continues to age, the impact of menopause on quality of life and long-term health will become increasingly felt. This will have implications not only for individual women but for society as a whole through the economic impact of lost work days and productivity. Menopausal health cannot be achieved through lifestyle measures alone, although these are the building blocks. There is a pressing need to continue research into understanding the impact of the long-term hypoestrogenic state now that menopause is a midlife point and particularly with premature ovarian insufficiency...  

 

Our Menopause World May 2016

Danckers L, Blümel JE, Witis S, et al. Personal and professional use of menopausal hormone therapy among gynecologists: A multinational study (REDLINC VII). Maturitas 2016;87:67-71

 

www.menopause.org.au/members/members-update

 

2016 ams congress 1

 
 
  Australasian Menopause Society
PO Box 511, Inverloch VIC 3996
Tel: +61 3 9428 8738
Email: ams@menopause.org.au 
Web: www.menopause.org.au

 
  Join the Australasian Menopause Society  
 
Forward this email to a friend
 
--